CN102106859A

CN102106859A - Breast cancer-resisting function and pharmaceutical preparation of maslinic acid

Info

Publication number: CN102106859A
Application number: CN2010102926887A
Authority: CN
Inventors: 林秀坤; 刘海洲; 廖德忠
Original assignee: Individual
Current assignee: Individual
Priority date: 2010-09-27
Filing date: 2010-09-27
Publication date: 2011-06-29

Abstract

The invention discloses novel medicinal application of maslinic acid to resistance for breast cancer and also discloses clinically-acceptable pharmaceutical preparation in forms of tablets, capsules, pills, injections, and the like which are prepared from the maslinic acid as raw material. The pharmaceutical preparation of the maslinic acid contains 1-99% of maslinic acid and 99-1% of pharmaceutical excipient (including other compatible medicaments). The maslinic acid and the pharmaceutical preparation thereof have excellent breast cancer resisting function which is embodied in remarkable inhibition activities of in vitro human breast cancer cells and nude mice transplanted tumors of the tumor cells. In addition, the active component of the pharmaceutical preparation is a Chinese medicine extract, so that the pharmaceutical preparation has the advantage of low toxicity relative to chemical treatment medicaments.

Description

The anti-breast cancer effect and the pharmaceutical preparation thereof of Crataegolic acid

Technical field

The present invention relates to application and the pharmaceutical preparation thereof of Crataegolic acid (Maslinic acid) aspect anti-breast cancer medicines, belongs to the field of Chinese medicines.

Background technology

Crataegolic acid (Maslinic acid) is a pentacyclic triterpenoid.Main source Fructus Jujubae, Fructus Canarii albi, Fructus Crataegi, Punica granatum L. and the Salvia japonica Thunb. etc. of extracting.

Malignant tumor is the commonly encountered diseases and the frequently-occurring disease of serious threat human health, and the exploitation of cancer therapy drug has become the key subjects of new drug research in this century.At present, from plant, seek the antitumor drug of high-efficiency low-toxicity, become the emphasis of domestic and international antitumor drug research.We find that in screening antitumor drug process Crataegolic acid has the effect of very strong inhibition breast cancer cell and solid tumor growth.

Before the present invention, do not find with the Crataegolic acid to be feedstock production pharmaceutical dosage form and the report that is used to prevent and treat breast cancer disease.Crataegolic acid is almost non-toxic, and natural resources of Chinese medicinal materials is very abundant, is a kind of very promising antitumor drug.

The Crataegolic acid another name: (2alpha, 3beta)-2,3-dihydroxy olive-12-alkene-28-acid; Maslinic acid; 2a-hydroxyl oleanolic acid.Molecular weight: 472.7; Molecular formula: C ₃₀H ₄₈O ₄

Chemical structural formula:

Summary of the invention

One of purpose of the present invention has provided the pharmaceutical preparation of Crataegolic acid;

Two of purpose of the present invention has provided the antineoplastic new usage of Crataegolic acid.

The objective of the invention is to be achieved through the following technical solutions:

Pharmaceutical preparation of the present invention contains the Crataegolic acid of 1%-99% and the excipient of 99%-1% (medicine that comprises other adapted), preferably contain the Crataegolic acid of 20%-80% and the excipient of 80%-20% (medicine that comprises other adapted), preferably contain the Crataegolic acid of 60%-70% and the excipient of 40%-30% (medicine that comprises other adapted).

Press practice of pharmacy, Crataegolic acid of the present invention can be prepared into the various clinical pharmaceutical dosage form as anti-breast cancer medicines, comprise the dosage form of oral formulations or parenterai administration.Said oral formulations selects any in tablet, capsule, pill, granule, microcapsule tablet, suspensoid, drop pill, oral liquid; Said parenterai administration dosage form is selected from a kind of in the middle of injection, aerosol, suppository or the subcutaneous administration dosage form.

Adjuvant in the anti-breast cancer medicines of the present invention is meant conventional excipient, as solvent, disintegrating agent, correctives, antiseptic, coloring agent, binding agent etc.The medicine that other compatibility in the antitumor drug of the present invention is used, the Crataegolic acid that refers to effective dose is certain medicine material, again compatibility other allowed the Chinese medicine or the chemical drugs that share.

Crataegolic acid pharmaceutical preparation of the present invention has the anti-breast cancer effect, is to be confirmed by following pharmacodynamics test.

Test example 1 has been investigated the inhibitory action of Crataegolic acid to external breast cancer cell

Cell: human breast cancer cell (MCF-7).For ocean institute of Chinese Academy of Sciences marine drug laboratory provides.

Medicine and reagent: ocean institute of Crataegolic acid (Maslinic acid) Chinese Academy of Sciences marine drug laboratory provides white powder; 5-fluorouracil (5-FU) Nantong elite pharmaceutical Co. Ltd product, lot number is 100402; MTT(SIGMA, USA); DMSO(SIGMA, USA); Trypsin SIGMA, USA); RPMI1640(GIBCO, Invitragen Co., USA); DMEM(GIBCO, Invitragen Co., USA); The top grade hyclone (GIBCO, Invitragen Co., USA); Superfine hyclone Fetal Bovine Serum(Hyclone).

Instrument: ultra cold storage freezer (Nature, USA), cell culture incubator (SANYO, Japan), inverted microscope (NIKON, Japan), microplate reader (Bio-Tek Instruments, Inooski, VT, USA), PH counts (Thermo orion, USA), superclean bench (FLC-Harbin Dong Lian instrument plant).

Experimental technique mtt assay: tumor cell line is gone down to posterity according to the conventional method cultivation, collect the exponential phase cell, regulate concentration of cell suspension 5 * 10 ⁴About individual/ml.Cell suspension is added in 96 well culture plates, and each hole adds 180 μ l.After placing 37 ℃ of constant incubators to cultivate 24 h, experimental group adds each concentration Crataegolic acid (with 5-FU as positive controls) 20 μ l/ holes, establishes 4 parallel holes for every group, and establishes blank well (only adding the medicinal solvent of dissolving) with zeroing.37 ℃ of incubators, cultivate 48 h after, with liquid-transfering gun liquid in 96 orifice plates is cleaned every hole, back and adds MTT(1 mg/ml) 30 μ l, put CO ₂Incubator is cultivated 4 h for 37 ℃, supernatant discarded, and every hole adds DMSO 150 μ l, puts shaking table and shakes up 30 min, detects under 492 nm with microplate reader, utilizes the SPSS statistical software, calculates cell mortality, asks for IC ₅₀

Result of the test shows, through the SPSS software statistics, the Crataegolic acid of variable concentrations has in various degree inhibitory action to the human breast cancer cell (MCF-7) that is used to test, and is certain dose-dependence, and the Crataegolic acid of variable concentrations is to suppression ratio, the IC of breast cancer cell ₅₀Value sees table 1 for details.

The Crataegolic acid of table 1 variable concentrations is to the suppression ratio of breast cancer cell

Test example 2 Crataegolic acids are to the tumor-inhibiting action of breast cancer cell transplanted tumor in nude mice

Laboratory animal: the BALB/c nude mice is available from Shanghai Slac Experimental Animal Co., Ltd., and animal licence numbering: SYXK (Shanghai) 2010-0047, totally 20, in 7 ~ 9 ages in week, body weight 20 ~ 22g is male Mus.Animal feeding and experiment are raised in the Affiliated Hospital of Qingdao University Experimental Animal Center for no special pathogen level barrier system.

Tumor cell inoculation: the human breast cancer cell of the trophophase of taking the logarithm (MCF-7) is made tumor cell suspension (1 * 10 ⁷Individual/as ml), to implant BALB/c male nude mouse armpit subcutaneous (about 0.3ml/ only), situations such as inoculation back routine observation mice spirit, diet and defecation.After going down to posterity once, with the aseptic taking-up of tumor tissues and be cut into big or small identical 2mm ³Fritter, it is subcutaneous to be seeded in the nude mice armpit with the trocar.

Test grouping and method: the major diameter of vernier caliper measurement tumor nodule (a), minor axis (b), by formula V=a * b ²* 0.52 calculates gross tumor volume, when subcutaneous transplantation tumor length to 100 mm ³After, selecting tumor nude mice of the same size, nude mice is weighed is divided into 3 groups with the table of random number method, is respectively negative control group, positive controls, Crataegolic acid group, every group of 5 nude mices.Drug level reaches and specifically is grouped as follows: (1) negative control group: lumbar injection 0.2ml normal saline; (2) positive drug matched group: the 5-FU of lumbar injection 30mg/kg; (3) Crataegolic acid group: 8mg/kg lumbar injection.Injection in per 3 days is once injected 10 times continuously, behind last administration 24 h, takes out the tumor piece, and it is heavy to measure tumor, calculates the average tumor suppression ratio at last.Adopt the SPSS software statistics, test data is with (average ± standard deviation) expression, and P is a significant difference significance criterion of meaning less than 0.01.Result of the test sees Table 2.

Table 2 Crataegolic acid is to the inhibitory action result of the test of MCF-7 transplanted tumor in nude mice (`X ± SD)

Annotate: compare * * P＜0.01 * P＜0.05 with matched group

By table 2 as seen, the transplanted tumor in nude mice of Crataegolic acid treatment group and 5-FU treatment group all has been subjected to inhibition in various degree than matched group, and the Crataegolic acid group to the influence of nude mice body weight all less than 1.0%, show that Crataegolic acid does not have obvious toxic-side effects.

Above-mentioned isolated test and bulk testing show that Crataegolic acid all has the obvious suppression effect to stripped and whole man's breast cancer cell, and does not have obvious toxic-side effects, and the prompting Crataegolic acid is a kind of very promising anti-breast cancer medicines.

The specific embodiment

The preparation of embodiment 1 tablet

Crataegolic acid 1000g, medical starch 100g, mix homogeneously is granulated as binding agent with an amount of ethanol, drying, through the pelletizing machine granulate, tabletting, every 0.30g, oral, each 1-2 sheet, twice of every day.

The preparation of embodiment 2 capsules

Crataegolic acid 1000g, medical starch 100g, mix homogeneously is granulated as binding agent with an amount of ethanol, and drying is crossed 120 mesh sieve granulate, dress 0# capsule, every 0.300g, each oral 1-2 grain, twice of every day.

The preparation of embodiment 3 drop pills

Polyethylene Glycol ₄₀₀₀400g, in water-bath, melt, add Crataegolic acid raw material 250g, stir, in the impouring insulating tube, regulate thermostat, make medicinal liquid under 80-90 ℃, splash in the liquid paraffin that cooled off (temperature ± 4 ℃), after dripping off, to blot paraffin oil on the pill impouring filter paper, add a small amount of Pulvis Talci again, mixing gets 10000 of Crataegolic acid drop pill.Oral, one time four, three times on the one, one after each meal.

The preparation of embodiment 4 granules

Crataegolic acid raw material 100g, starch 1000g, Icing Sugar 500g, mix homogeneously is used an amount of alcohol granulation, and drying, granulate, packing are promptly.Oral, a 5g, twice on the one.

The preparation of embodiment 5 microencapsule tablets

Take by weighing stearic acid 12g and 18ml Herba Origani oil respectively as compound recipe capsule material, take by weighing Crataegolic acid 80g as capsule core material, by the spray congealing encystation, capsule directly is 10-100 μ m with compressed air.Then with microcapsule and microcrystalline Cellulose mixing, add the mixed encystation material of 12% ethyl cellulose alcoholic solution, make granule by 18 order nylon mesh,, placed exsiccator interior 24 hours in oven dry below 50 ℃, add 1%-3% magnesium stearate tabletting, get the Crataegolic acid microencapsule tablet, sheet heavily is 0.4g, and is oral, a 1-2 sheet, twice on the one.

The preparation of embodiment 6 injections

Crataegolic acid 40g, propylene glycol 50ml, PEG400 100ml, water for injection 600ml mixes heating in water bath 30 minutes, add benzyl alcohol 90ml, reuse water for injection adds to 1800ml, handles 10 minutes in ultrasound wave, heats 30 minutes in water-bath again, adjust pH is 5.5-6.5, filter, embedding, sterilization is promptly.Every 3ml, intramuscular injection, a 3ml, twice on the one.

Claims

1. pharmaceutical preparation that is used for the treatment of breast carcinoma is characterized in that containing the Crataegolic acid for the treatment of effective dose and one or more pharmaceutically acceptable pharmaceutical excipients, or can with the other medicines of Crataegolic acid prescription.

2. pharmaceutical preparation according to claim 1, but it is characterized in that containing Crataegolic acid and the pharmaceutical excipient of 99%-1% or the medicine of other prescription of 1%-99%.

3. pharmaceutical preparation according to claim 2, but it is characterized in that containing Crataegolic acid and the pharmaceutical excipient of 80%-20% or the medicine of other prescription of 20%-80%.

4. pharmaceutical preparation according to claim 3, but it is characterized in that containing Crataegolic acid and the pharmaceutical excipient of 40%-30% or the medicine of other prescription of 60%-70%.

5. pharmaceutical preparation according to claim 1 is characterized in that said medicine is the dosage form of oral formulations or parenterai administration.

6. pharmaceutical preparation according to claim 5 is characterized in that said oral formulations is selected from any in tablet, pill, capsule, granule, microcapsule tablet, suspensoid, drop pill, the oral liquid.

7. pharmaceutical preparation according to claim 5 is characterized in that said parenterai administration dosage form is selected from any in the middle of injection, aerosol, suppository or the subcutaneous administration dosage form.

8. the application of Crataegolic acid in the preparation anti-breast cancer medicines.

9. purposes according to Claim 8 is characterized in that said anti-breast cancer is meant the growth that suppresses human breast cancer cell (MCF-7) and nude mice transplanted tumor thereof.